English
Русский
Recently, GE healthcare signed a cooperation agreement with HistoSonics in the United States to use Logiq E10 series ultrasound for Edison, the liver therapy system being developed by HistoSonics. Edison™ system, currently in development, uses the novel science of histotripsy to non-invasively destroy targeted liver tissue. HistoSonics intends to utilize GE Healthcare's LOGIQ E10 Series, currently the most technologically advanced ultrasound platform for guiding radiology interventions, to provide treating physicians with continuous visualization for key and unique elements of the histotripsy therapy procedure, including planning, monitoring, and immediate post-treatment verification. This agreement is aimed to support HistoSonics' efforts to launch their EdisonTM system leveraging their deep domain expertise along with GE Healthcare's world-class ultrasound imaging technologies, digital infrastructure, data analytics and clinical decision support capabilities.
Edison is a non-invasive treatment system that guides the sound beam to transmit vibration to organs in the body without any incisions or needles, does not damage the skin, and has the ability to destroy the target tissue at the subcellular level. It uses the cavitation effect of ultrasonic waves and uses pulsed sound waves to induce “bubble clouds” of only a few millimeters in size from the naturally present gas in the target tissue. These bubble clouds form and collapse within a few microseconds, producing a strong enough mechanical force to destroy target tissues at the cellular and subcellular levels in a noninvasive and heat-free manner.
The HistoSonics System is investigational and is not available for sale in the United States or Europe. It is limited to investigational use in the approved IDE and European studies.
About HistoSonics
HistoSonics was established in 2009, is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on the continued development of its EdisonTM Platform, global clinical studies, and new strategic projects including future clinical applications and platforms. has conducted 8 rounds of financing and obtained US1126.8 million in funds. Investors include Johnson & Johnson Innovation (JJDC), Varian and other companies familiar with the industry.Has offices in Ann Arbor, Michigan and Minneapolis, MN.
